Anti-tumor efficacy and biomarker evaluation of agonistic anti-OX40 antibodies in preclinical models

Overview of attention for article published in Journal for Immunotherapy of Cancer, November 2014

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (53rd percentile)

Mentioned by

patent: 4 patents

Readers on

mendeley: 5 Mendeley

Summary Patents

So far, Altmetric has seen 4 patents that reference this research output.

IMMUNOMODULATORY PEPTIDES

Application WO-2022081426-A1

World Intellectual Property Organisation (WIPO)

LAG3 BINDING PEPTIDES

Application WO-2022026496-A2

World Intellectual Property Organisation (WIPO)

COMBINATION THERAPY WITH TARGETED OX40 AGONISTS

Application WO-2019086497-A3

World Intellectual Property Organisation (WIPO)

METHODS OF TREATING CANCER USING ANTI-OX40 ANTIBODIES

Application WO-2016200836-A1

World Intellectual Property Organisation (WIPO)

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity.